The Journal of the American Medical Association (JAMA) just published a ten year patient follow-up to a phase III clinical study on a Soft Tissue Sarcoma Study.
With Invited Commentary - Technological Advances, Biologic Rationales, and the Associated Success of Chemotherapy With Hyperthermia in Improved Outcomes in Patients With Sarcoma by Mark W. Dewhirst, DVM, Ph.D.; David Kirsch, MD, PhD
Under the organization of the European Society of Hyperthermic Oncology, the study was conducted in 9 centers located in Germany, Norway, Austria, and the United States using the BSD-2000 Deep Regional Hyperthermia System. This study enrolled 365 soft tissue sarcoma patients (18-70 years old) that were matched and entered into a double-blind study. One group received neoadjuvant chemotherapy consisting of doxorubicin, ifosfamide, and etoposide [CT] treatment and the other group received the same chemotherapy along with a course of hyperthermia [HT].
For non-clinicians, we have done our best to provide the salient points in the above info-graphic. The full article can be found on the JAMA website here.
We feel that the results are astonishing. The HEADLINE: chemotherapy plus hyperthermia equals better results and extended life. #heatmatters